TOG Review (RCOG Journal)
MRCOG Part 2
Maternal Medicine
Peripartum cardiomyopathy
Key Statistics
- LVEF <45% — Diagnostic echo criterion (ESC 2010)
- 78% — Present within 4 months of birth
- 50–80% — Recover LV function (LVEF ≥50%)
Don't-miss facts
-
Diagnostic criterion: LVEF <45% on echo, end of pregnancy to 6 months postpartum, no other cause — make the diagnosis, don’t just exclude it
-
MBRRACE 2019 red flags: tachypnoea, chest pain, persistent tachycardia, orthopnoea — always fully investigate
-
In pregnancy avoid ACEi / ARB / MRA; use metoprolol + hydralazine/nitrate + loop diuretic + salt restriction; LMWH for anticoagulation
-
Anticoagulate if LVEF ≤35% and/or on bromocriptine; continue anticoagulation 6–8 months postpartum
-
Bromocriptine 2.5 mg od ≥1 week; if EF <25%: 2.5 mg bd ×2 weeks then 2.5 mg od ×6 weeks — always with anticoagulation
-
Cardiogenic shock: levosimendan 0.1 µg/kg/min for 24 h preferred over catecholamines; IV nitrate only if systolic BP
110 mmHg; target SpO₂ >95%
-
Third stage: slow oxytocin infusion; second line misoprostol/carboprost; never ergometrine or long-acting oxytocin analogues
-
Contraception: IUD (fit in hospital, no antibiotic prophylaxis) or progestogen LARC; avoid combined hormonal contraception and barrier methods
Numbers to recall
78% present <4 months postpartum Ventricular arrhythmia 20% VTE 2.2–6.8% Recovery 50–80% (LVEF ≥50%)
Mortality ~10% Relapse 20% even after full recovery 50% deteriorate if persistent LV dysfunction
~5% need mechanical support/transplant
Abbreviation Key
- PPCM — peripartum cardiomyopathy
- ARB — angiotensin receptor blocker
- ESC — European Society of Cardiology
- ARNI — angiotensin receptor neprilysin inhibitor
- MBRRACE — Mothers and Babies: Reducing Risk through Audits
- MRA — mineralocorticoid receptor antagonist and Confidential Enquiries
- BNP — brain natriuretic peptide
- LVEF — left ventricular ejection fraction
- NT-proBNP — N-terminal pro-brain natriuretic peptide
- LVEDD — left ventricular end-diastolic diameter
- sFlt-1 — soluble fms-like tyrosine kinase receptor 1
- ACEi — angiotensin-converting enzyme inhibitor
- LMWH — low-molecular-weight heparin
Source: Kulkarni A, Squire G, Hogrefe K, Osman MW. Peripartum cardiomyopathy. The Obstetrician & Gynaecologist 2021;23:278–289. doi:10.1111/tog.12770
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).